UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alterations in T cell receptor and signal transduction molecules in melanoma patients

Clinical cancer research, 1995-11, Vol.1 (11), p.1327-1335

1995

Volltextzugriff (PDF)

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

Nature medicine, 1999-10, Vol.5 (10), p.1171-1177

1999

Volltextzugriff (PDF)

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin

The New England journal of medicine, 1993-03, Vol.328 (11), p.756-761

1993

Volltextzugriff (PDF)

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

Journal of clinical oncology, 1996-08, Vol.14 (8), p.2234-2241

1996

Volltextzugriff (PDF)

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

Annals of internal medicine, 1988-12, Vol.109 (12), p.953

1988

Volltextzugriff (PDF)

T cell activation via the disialoganglioside GD3: analysis of signal transduction

Journal of leukocyte biology, 1996-10, Vol.60 (4), p.533-539

1996

Volltextzugriff (PDF)

Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma

JNCI : Journal of the National Cancer Institute, 1996-01, Vol.88 (1), p.44-49

1996

Volltextzugriff (PDF)

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2

The Journal of immunology (1950), 1988-02, Vol.140 (4), p.1335-1340

1988

Volltextzugriff (PDF)

Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2

Journal of clinical oncology, 1993-04, Vol.11 (4), p.652-660

1993

Volltextzugriff (PDF)

Dose-related immunologic effects of levamisole in patients with cancer

Journal of clinical oncology, 1993-01, Vol.11 (1), p.125-135

1993

Volltextzugriff (PDF)

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2

Cancer research (Chicago, Ill.), 1988-11, Vol.48 (22), p.6597-6602

1988

Volltextzugriff (PDF)

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients

Journal of immunotherapy (1997), 1996-07, Vol.19 (4), p.296-308

1996

Volltextzugriff (PDF)

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma

Journal of immunotherapy (1997), 1996-09, Vol.19 (5), p.364-374

1996

Volltextzugriff (PDF)

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Advanced Malignancy: A Phase Ib Trial

JNCI : Journal of the National Cancer Institute, 1990-04, Vol.82 (8), p.697-703

1990

Volltextzugriff (PDF)

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors : a phase IA/B study

Cancer research (Baltimore), 1992-05, Vol.52 (9), p.2394-2401

1992

Volltextzugriff (PDF)

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

Journal of clinical oncology, 1989-02, Vol.7 (2), p.276-284

1989

Volltextzugriff (PDF)

MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of Interleukin-15: Assay qualification, standardization and statistical analysis

Journal of immunological methods, 2009-08, Vol.348 (1), p.83-94

2009

Volltextzugriff (PDF)

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

Journal of clinical oncology, 1989-04, Vol.7 (4), p.486-498

1989

Volltextzugriff (PDF)

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study

Journal of clinical oncology, 1990-04, Vol.8 (4), p.721-730

1990

Volltextzugriff (PDF)

A Phase I Clinical Trial of Flavone-8-Acetic Acid in Combination With Interleukin 2

JNCI : Journal of the National Cancer Institute, 1995-01, Vol.87 (2), p.134-136

1995

Volltextzugriff (PDF)

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies

Journal of clinical oncology, 1992-07, Vol.10 (7), p.1141-1152

1992

Volltextzugriff (PDF)

Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma

Journal of immunotherapy, 1991-10, Vol.10 (5), p.355-362

1991

Volltextzugriff (PDF)

Use of Prophylactic Antibiotics for Prevention of Intravascular Catheter-Related Infections in Interleukin-2-Treated Patients

JNCI : Journal of the National Cancer Institute, 1989-08, Vol.81 (15), p.1190-1193

1989

Volltextzugriff (PDF)

Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and light

Cancer research (Chicago, Ill.), 1983-11, Vol.43 (11), p.5252-5257

1983

Volltextzugriff (PDF)

Hypothyroidism after interleukin-2 therapy

Journal of clinical oncology, 1989-05, Vol.7 (5), p.686-687

1989

Volltextzugriff (PDF)

1 – 25 von 131

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(128)
Tagungsberichte
(3)

Sprache

Englisch
(130)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alterations in T cell receptor and signal transduction molecules in melanoma patients

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

T cell activation via the disialoganglioside GD3: analysis of signal transduction

Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2

Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2

Dose-related immunologic effects of levamisole in patients with cancer

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Advanced Malignancy: A Phase Ib Trial

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors : a phase IA/B study

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of Interleukin-15: Assay qualification, standardization and statistical analysis

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study

A Phase I Clinical Trial of Flavone-8-Acetic Acid in Combination With Interleukin 2

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies

Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma

Use of Prophylactic Antibiotics for Prevention of Intravascular Catheter-Related Infections in Interleukin-2-Treated Patients

Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and light

Hypothyroidism after interleukin-2 therapy

Suchergebnisse filtern